Michael Grayling

Michael Grayling

Newcastle University Research Fellow

Population Health Sciences Institute

Biography

Background

I am a Newcastle University Research Fellow in Biostatistics. I have been at Newcastle University since November 2018. Prior to this I was a statistician at the MRC Biostatistics Unit, University of Cambridge.

I am interested in the design and analysis of clinical trials. My work has involved a mixture of developing novel statistical methodology for trials, comparing existing method performance, and collaborating on real trials. I also work on developing user-friendly software for trial design; I created and maintain the multiarm app for designing fixed-sample and adaptive (group-sequential/drop-the-losers) multi-arm trials, available here.

PhD students

Contact

Interests
  • Adaptive design
  • Early phase oncology trials
  • Crossover trials
  • Stepped-wedge trials
Education

  • Wellcome Trust PhD Programme in Mathematical Genomics and Medicine, 2012-16

    MRC Biostatistics Unit, University of Cambridge

  • Systems Biology MSci, 2011-12

    University of Cambridge

  • Mathematics BA (Hons), 2008-11

    University of Cambridge

Publications

Quickly discover relevant content by filtering publications.
Aritra Mukherjee, Michael J. Grayling, James M. S. Wason (2022). Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. World Neurosurgery.

Cite DOI URL

Aritra Mukherjee, James M. S. Wason, Michael J. Grayling (2022). When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. European Journal of Cancer.

Cite DOI URL

Michael J. Grayling, Adrian P. Mander (2022). Optimised point estimators for multi-stage single-arm phase II oncology trials. Journal of Biopharmaceutical Statistics.

Cite DOI URL

Michael J. Grayling, Martina McMenamin, Robert Chandler, Rakesh Heer, James M. S. Wason (2022). Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. BMC Cancer.

Cite DOI URL

Michael J. Grayling, James M. S. Wason, Sofía S. Villar (2022). Response adaptive intervention allocation in stepped-wedge cluster randomized trials. Statistics in Medicine.

Cite DOI URL

Michael J. Grayling, Adrian P. Mander (2021). Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. JCO Precision Oncology.

Cite DOI URL

Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason J (2021). Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential. BMC Rheumatol 2021; 5:21.

DOI

Grayling MJ, Mander AP (2021). Accounting for variation in the required sample size in the design of group-sequential trials. Contemp Clin Trials 2021; 107:106459.

DOI

Kunzmann K, Grayling MJ, Lee KM, Robertson DS, Rufibach K, Wason JMS (2021). A review of Bayesian perspectives on sample size derivation for confirmatory trials. Am Stat 2021; DOI:10.1080/00031305.2021.1901782.

Ouma LO, Grayling MJ, Zheng H, Wason J (2021). Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharm Stat 2021; doi:10.1002/pst.2119.

DOI

Ward M, Grayling M, Wason J, Welton NJ, Haji-Ali AL, Jalal H, Thom H (2020). PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections. Value Health 2020; 23:S738.

DOI

McClelland G, Wilson N, Shaw L, Grayling M, Haworth D, Price CI (2020). Ambulance documentation of stroke symptoms during the UK COVID-19 'Stay at Home' message. Emerg Med J 2020; 38:83-84.

DOI

McClelland G, Shaw G, Thompson L, Wilson N, Grayling M (2020). Impact of the COVID-19 lockdown on hangings attended by emergency medical services. Resuscitation 2020; 157:89-90.

DOI

Law M, Grayling MJ, Mander AP (2020). A stochastically curtailed two-arm randomised phase II trial design for binary outcomes. Pharm Stat 2020; 20:212-28.

DOI

McMenamin M, Grayling MJ, Berglind A, Wason JMS (2020). Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. medRxiv 2020.

DOI

Grayling MJ, Wheeler GM (2020). A review of available software for adaptive clinical trial design. Clin Trials 2020;17:323-31.

DOI

Grayling MJ, Wason JMS (2020). A web application for the design of multi-arm clinical trials. BMC Cancer 2020; 20:80.

DOI

Wych J, Grayling MJ, Mander AP (2019). Sample size re-estimation in crossover trials: Application to the AIM HY-INFORM study. Trials 2019;20:665.

DOI

Grayling MJ, Mander AP, Wason JMS (2019). Two-stage adaptive designs for three-treatment bioequivalence studies. Stat Biopharm Res 2019; 11:360-74.

DOI

Grayling MJ, Dimairo M, Mander AP, Jaki TF (2019). A review of perspectives on the use of randomization in phase II oncology trials. JNCI: J Natl Cancer I 2019; 111:1255-62.

DOI .bib .enw .ris

See all publications